Gastric function measurements in drug development

British Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2003, Pages 156-164

  Pohle, Thorsten ^a   Domschke, Wolfram ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Drug development; EGG; Gastric function; Gastroparesis; GORD; pH metry

Indexed keywords

BICARBONATE; BOTULINUM TOXIN; CISAPRIDE; CYANOCOBALAMIN; DIGOXIN; DOMPERIDONE; ERYTHROMYCIN; ESOMEPRAZOLE; GASTRIN; GASTROINTESTINAL AGENT; INTRINSIC FACTOR; ITRACONAZOLE; MESALAZINE; METOCLOPRAMIDE; MUCIN; OMEPRAZOLE; PEPSIN A; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SECRETIN; TEGASEROD; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

BREATH ANALYSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; ELECTROGASTROGRAPHY; ELECTROSTIMULATION; ENDOCRINE FUNCTION; ENTERITIS; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; MYOELECTRICITY; NONHUMAN; PARTICLE SIZE; PEPTIC ULCER; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; SCHILLING TEST; STOMACH ACID SECRETION; STOMACH EMPTYING; STOMACH FUNCTION; STOMACH JUICE; STOMACH MOTILITY; STOMACH PARESIS; STOMACH PH; STOMACH SCINTISCANNING; STOMACH SECRETION;

ENDOCRINE GLANDS; EXOCRINE GLANDS; GASTRIC EMPTYING; GASTRINS; GASTROESOPHAGEAL REFLUX; GASTROPARESIS; HUMANS; HYDROGEN-ION CONCENTRATION; STOMACH;

EID: 0042697139     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01935.x     Document Type: Review

References (57)

1. Amidon GL, Lennernas H, Shah VP, Crisoon JR. A theoretical basis for a biopharmaceutic drug classification the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
2. Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull 2002; 25: 149-164.
3. Sarna SK. Cyclic motor activity; migrating motor complex. Gastroenterology 1985; 89: 894-913.
4. Peghini P, Katz PO, Gilbert J, et al. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-1339.
5. Hunt RH. Importance of pH control in the management of GERD. Ann Intern Med 1999; 159: 649-657.
6. Rademaker JW, Rainsford KD, Stetsko PI, et al. The effect of indomethacin-induced gastric mucosal injury on 24 h intragastric acidity and plasma gastrin concentration in human volunteers. Aliment Pharmacol Ther 1995; 9: 625-631.
7. Viani F, Verdu EF, Idstrom JP, et al. Effect of omeprazole on regional and temporal variations in intragastric acidity. Digestion 2002; 65: 2-10.
8. Bell N, Karol MN, Sachs G, Greski-Roses P, Jennings DE, Hunt RH. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther 2001; 15: 105-113.
9. Feldman M. Gastric secretion. normal and abnormal. In Sleisenger and Fordtran's Gastrointestinal and liver disease: Pathophysiology/Diagnosis/Management, eds. Feldman, M, Scharschmidt, BF, Sleisenger, MH. Philadelphia: W. B. Saunders, 1998; 587-603.
10. Verhagen MA, Samsom M, Jebbink RJ, Smout AJ. Clinical relevance of antroduodenal manometry. Eur J Gastroenterol Hepatol 1999; 11: 523-528.
11. Leahy A, Besherdas K, Clayman C, Mason I, Epstein O. Abnormalities of the electrogastrogram in functional gastrointestinal disorders. Am J Gastroenterol 1999; 94: 1023-1028.
12. Chen JDZ, Pan J, McCallum RW. Chnical significance of gastric myoelectric dysrhythmias. Dig Dis 1995; 13: 275-290.
13. Stern RM, Koch KL, Stewart WR, Wasey MW. Electrogastrography - Current issues in validation and methodology. Psychophysiology 1987; 24: 55-64.
14. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36: 609-615.
15. Thomforde GM, Camilleri M, Phillips SF, Forstrom LA. Evaluation of an inexpensive screening scintigraphic test of gastric emptying. J Nucl Med 1995; 36: 93-96.
16. 13C acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology 1995; 108: 1048-1055.
17. Bromer MQ, Kantor SB, Wagner DA, Knight LC, Maurer AH, Parkmer HP. Simultaneous measurement of gastric emptying with a simple muffin meal using 13C octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms. Dig Dis Sci 2002; 47: 1657-1663.
18. Gatti C, di Abriola FF, Dall'Oglio L, Villa M, Franchini F, Amarri S. Is the 13C-acetate breath test a valid procedure to analyse gastric emptying in children? J Pediatr Surg 2000; 35: 62-65.
19. Bluck LJ, Harding M, French S, Wright A, Halliday D, Coward WA. Measurement of gastric emptying in man using deuterated octanoic acid. Rapid Commun Mass Spectrom 2002; 16: 127-133.
20. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-867.
21. Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-958.
22. Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castel DO. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001; 15: 519-524.
23. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-632.
24. Storr M, Meining A, Allescher HD. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 2000; 18: 93-102.
25. Pohle T, Domschke W. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 2000; 385: 317-323.
26. Freys SM, Fuchs KH, Heimbucher J, Thiede A. Tailored augmentation of the lower esophageal sphincter in experimental antireflux operations. Surg Endosc 1997; 11: 1183-1188.
27. Chrysos E, Athanasakis E, Zoras OJ, Tsiaoussis J, Xynos E. Twenty-four-hour ambulatory versus stationary esophageal manometry in the evaluation of esophageal motility in patients with gastroesophageal reflux disease. Digestion 2002; 66: 1-8.
28. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600-1605.
29. Horowitz M, Edelbroek M, Fraser R, Maddox A, Wishart J. Disordered gastric motor function in diabetes mellitus. Scand J Gastroenterol 1991; 26: 673-684.
30. Malagelada JR. Diabetic gastroparesis. Semin Gastrointest Dis 1995; 4: 181-186.
31. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90: 1919-1925.
32. MacGregor IL, Gueller R, Watts HD, Meyer JH. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 1976; 70: 190-196.
33. Achem-Karam SR, Funakoshi A, Vinik AI, Owyang C. Plasma motilin concentrations and interdigestive migrating motor complex in diabetic gastroparesis: effect of metoclopramide. Gastroenterology 1985; 88: 492-499.
34. Brown CK, Khanderia U. Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. Clin Pharmacol 1990; 9: 357-365.
35. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJ. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1-9.
36. Camilleri N, Malagelada JR, Abell TL, Rown ML, Hench V, Zinsmeister AR. Effect of six weeks of treatment with cisapride on gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96: 704-712.
37. Johnson AG. The effects of cisapride on antroduodenal coordination and gastric emptying. Scand J Gastroenterol Suppl 1989; 165: 36-43.
38. Feldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171-174.
39. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 1028-1031.
40. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277-289.
41. Fioramonti J, Million M, Bueno L. Investigations on a 5HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology 1998; 114: A752 (Abstract).
42. 4 receptor partial agonist, accelerates gastrointestinal transit. Gastroenterology 2000; 118: A845 (Abstract).
43. Appel S, Kumle A, Hubert M, Duvauchelle T. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist. J Clin Pharmacol 1997; 37: 229-237.
44. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 2002; 55: 920-923.
45. Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002; 97: 1653-1660.
46. Waterfall WE, Miller D, Ghista DN. Electrical stimulation of the human stomach. Dig Dis Sci 1985; 30: 799 (Abstract).
47. Familoni BO, Abell TL, Voeller G, Salem A, Garbere O. Electrical stimulation at a higher frequency than basal rate in human stomach. Dig Dis Sci 1997; 42: 885-891.
48. van der Voort IR, Dietl KH, Menzel J, Pohle T, Senninger N, Domschke W. Therapie der Gastroparese - Langzeitergebnisse der elektrischen Stimulation. Med Klin 2002; 97: (Abstract-Band, I): 91 (Abstract).
49. Bortolotti M. The 'electrical way' to cure gastroparesis. Am J Gastroenterol 2002; 97: 1874-1883.
50. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa®) dosed as either tablet or sachet. Aliment Pharmacol Ther 2000; 14: 163-169.
51. Mulder CJJ, van den Hazel SJ. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Med Inflamm 1998; 7: 135-136.
52. Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, van Vliet A. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 1991; 115: 540-545.
53. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37: 535-540.
54. Shelton MJ, Adams JM, Hewitt RG, Steinwandel C, DeRemer M, Cousins S, Morse GD. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy 1997; 17: 438-444.
55. Lee HT, Lee YJ, Chung SJ, Shim CK. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats. Res Commun Mol Pathol Pharmacol 2000; 108: 311-323.
56. Amir I, Anwar N, Baraona E, Lieber CS. Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. Life Sci 1996; 58: 511-518.
57. Kechagias S, Jonsson KA, Norlander B, Carlsson B, Jones AW. Low-dose aspirin decreases blood alcohol concentrations by delaying gastric emptying. Eur J Clin Pharmacol 1997; 53: 241-246.